The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Anti-spasmodic Drugs Market Research Report 2024
Synopsis
Antispasmodic drugs such as dicyclomine (Bentyl) and hyoscyamine (Levsin) relieve the stomach cramps brought on by IBS by relaxing the smooth muscle of the gut. They also may cause constipation, so they aren't usually prescribed for people who suffer from IBS-C. Other side effects are dry mouth, drowsiness, and blurred vision.
The global Anti-spasmodic Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Anti-spasmodic Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Anti-spasmodic Drugs.
Report Scope
The Anti-spasmodic Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Anti-spasmodic Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Anti-spasmodic Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
Allergan
Ipsen
Teva Pharmaceuticals
Novartis
Johnson & Johnson
Takeda Pharmaceutical
Sun Pharmaceutical Industries
Merz Pharma
Mylan
Fresenius Kabi
Endo International
Daewoong Pharmaceutical
Acorda Therapeutics
SteriMax
Emcure Pharmaceuticals
Sawai Pharmaceutical
Orient Pharma
Segment by Type
Antimuscarinics
Smooth Muscle Relaxants
Segment by Application
Offline Channel
Online Channel
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Anti-spasmodic Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Antispasmodic drugs such as dicyclomine (Bentyl) and hyoscyamine (Levsin) relieve the stomach cramps brought on by IBS by relaxing the smooth muscle of the gut. They also may cause constipation, so they aren't usually prescribed for people who suffer from IBS-C. Other side effects are dry mouth, drowsiness, and blurred vision.
The global Anti-spasmodic Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Anti-spasmodic Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Anti-spasmodic Drugs.
Report Scope
The Anti-spasmodic Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Anti-spasmodic Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Anti-spasmodic Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
Allergan
Ipsen
Teva Pharmaceuticals
Novartis
Johnson & Johnson
Takeda Pharmaceutical
Sun Pharmaceutical Industries
Merz Pharma
Mylan
Fresenius Kabi
Endo International
Daewoong Pharmaceutical
Acorda Therapeutics
SteriMax
Emcure Pharmaceuticals
Sawai Pharmaceutical
Orient Pharma
Segment by Type
Antimuscarinics
Smooth Muscle Relaxants
Segment by Application
Offline Channel
Online Channel
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Anti-spasmodic Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Anti-spasmodic Drugs Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Antimuscarinics
1.2.3 Smooth Muscle Relaxants
1.3 Market by Application
1.3.1 Global Anti-spasmodic Drugs Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Offline Channel
1.3.3 Online Channel
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Anti-spasmodic Drugs Market Perspective (2019-2030)
2.2 Anti-spasmodic Drugs Growth Trends by Region
2.2.1 Global Anti-spasmodic Drugs Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Anti-spasmodic Drugs Historic Market Size by Region (2019-2024)
2.2.3 Anti-spasmodic Drugs Forecasted Market Size by Region (2025-2030)
2.3 Anti-spasmodic Drugs Market Dynamics
2.3.1 Anti-spasmodic Drugs Industry Trends
2.3.2 Anti-spasmodic Drugs Market Drivers
2.3.3 Anti-spasmodic Drugs Market Challenges
2.3.4 Anti-spasmodic Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Anti-spasmodic Drugs Players by Revenue
3.1.1 Global Top Anti-spasmodic Drugs Players by Revenue (2019-2024)
3.1.2 Global Anti-spasmodic Drugs Revenue Market Share by Players (2019-2024)
3.2 Global Anti-spasmodic Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Anti-spasmodic Drugs Revenue
3.4 Global Anti-spasmodic Drugs Market Concentration Ratio
3.4.1 Global Anti-spasmodic Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Anti-spasmodic Drugs Revenue in 2023
3.5 Anti-spasmodic Drugs Key Players Head office and Area Served
3.6 Key Players Anti-spasmodic Drugs Product Solution and Service
3.7 Date of Enter into Anti-spasmodic Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Anti-spasmodic Drugs Breakdown Data by Type
4.1 Global Anti-spasmodic Drugs Historic Market Size by Type (2019-2024)
4.2 Global Anti-spasmodic Drugs Forecasted Market Size by Type (2025-2030)
5 Anti-spasmodic Drugs Breakdown Data by Application
5.1 Global Anti-spasmodic Drugs Historic Market Size by Application (2019-2024)
5.2 Global Anti-spasmodic Drugs Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Anti-spasmodic Drugs Market Size (2019-2030)
6.2 North America Anti-spasmodic Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Anti-spasmodic Drugs Market Size by Country (2019-2024)
6.4 North America Anti-spasmodic Drugs Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Anti-spasmodic Drugs Market Size (2019-2030)
7.2 Europe Anti-spasmodic Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Anti-spasmodic Drugs Market Size by Country (2019-2024)
7.4 Europe Anti-spasmodic Drugs Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Anti-spasmodic Drugs Market Size (2019-2030)
8.2 Asia-Pacific Anti-spasmodic Drugs Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Anti-spasmodic Drugs Market Size by Region (2019-2024)
8.4 Asia-Pacific Anti-spasmodic Drugs Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Anti-spasmodic Drugs Market Size (2019-2030)
9.2 Latin America Anti-spasmodic Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Anti-spasmodic Drugs Market Size by Country (2019-2024)
9.4 Latin America Anti-spasmodic Drugs Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Anti-spasmodic Drugs Market Size (2019-2030)
10.2 Middle East & Africa Anti-spasmodic Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Anti-spasmodic Drugs Market Size by Country (2019-2024)
10.4 Middle East & Africa Anti-spasmodic Drugs Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Detail
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Anti-spasmodic Drugs Introduction
11.1.4 Pfizer Revenue in Anti-spasmodic Drugs Business (2019-2024)
11.1.5 Pfizer Recent Development
11.2 Allergan
11.2.1 Allergan Company Detail
11.2.2 Allergan Business Overview
11.2.3 Allergan Anti-spasmodic Drugs Introduction
11.2.4 Allergan Revenue in Anti-spasmodic Drugs Business (2019-2024)
11.2.5 Allergan Recent Development
11.3 Ipsen
11.3.1 Ipsen Company Detail
11.3.2 Ipsen Business Overview
11.3.3 Ipsen Anti-spasmodic Drugs Introduction
11.3.4 Ipsen Revenue in Anti-spasmodic Drugs Business (2019-2024)
11.3.5 Ipsen Recent Development
11.4 Teva Pharmaceuticals
11.4.1 Teva Pharmaceuticals Company Detail
11.4.2 Teva Pharmaceuticals Business Overview
11.4.3 Teva Pharmaceuticals Anti-spasmodic Drugs Introduction
11.4.4 Teva Pharmaceuticals Revenue in Anti-spasmodic Drugs Business (2019-2024)
11.4.5 Teva Pharmaceuticals Recent Development
11.5 Novartis
11.5.1 Novartis Company Detail
11.5.2 Novartis Business Overview
11.5.3 Novartis Anti-spasmodic Drugs Introduction
11.5.4 Novartis Revenue in Anti-spasmodic Drugs Business (2019-2024)
11.5.5 Novartis Recent Development
11.6 Johnson & Johnson
11.6.1 Johnson & Johnson Company Detail
11.6.2 Johnson & Johnson Business Overview
11.6.3 Johnson & Johnson Anti-spasmodic Drugs Introduction
11.6.4 Johnson & Johnson Revenue in Anti-spasmodic Drugs Business (2019-2024)
11.6.5 Johnson & Johnson Recent Development
11.7 Takeda Pharmaceutical
11.7.1 Takeda Pharmaceutical Company Detail
11.7.2 Takeda Pharmaceutical Business Overview
11.7.3 Takeda Pharmaceutical Anti-spasmodic Drugs Introduction
11.7.4 Takeda Pharmaceutical Revenue in Anti-spasmodic Drugs Business (2019-2024)
11.7.5 Takeda Pharmaceutical Recent Development
11.8 Sun Pharmaceutical Industries
11.8.1 Sun Pharmaceutical Industries Company Detail
11.8.2 Sun Pharmaceutical Industries Business Overview
11.8.3 Sun Pharmaceutical Industries Anti-spasmodic Drugs Introduction
11.8.4 Sun Pharmaceutical Industries Revenue in Anti-spasmodic Drugs Business (2019-2024)
11.8.5 Sun Pharmaceutical Industries Recent Development
11.9 Merz Pharma
11.9.1 Merz Pharma Company Detail
11.9.2 Merz Pharma Business Overview
11.9.3 Merz Pharma Anti-spasmodic Drugs Introduction
11.9.4 Merz Pharma Revenue in Anti-spasmodic Drugs Business (2019-2024)
11.9.5 Merz Pharma Recent Development
11.10 Mylan
11.10.1 Mylan Company Detail
11.10.2 Mylan Business Overview
11.10.3 Mylan Anti-spasmodic Drugs Introduction
11.10.4 Mylan Revenue in Anti-spasmodic Drugs Business (2019-2024)
11.10.5 Mylan Recent Development
11.11 Fresenius Kabi
11.11.1 Fresenius Kabi Company Detail
11.11.2 Fresenius Kabi Business Overview
11.11.3 Fresenius Kabi Anti-spasmodic Drugs Introduction
11.11.4 Fresenius Kabi Revenue in Anti-spasmodic Drugs Business (2019-2024)
11.11.5 Fresenius Kabi Recent Development
11.12 Endo International
11.12.1 Endo International Company Detail
11.12.2 Endo International Business Overview
11.12.3 Endo International Anti-spasmodic Drugs Introduction
11.12.4 Endo International Revenue in Anti-spasmodic Drugs Business (2019-2024)
11.12.5 Endo International Recent Development
11.13 Daewoong Pharmaceutical
11.13.1 Daewoong Pharmaceutical Company Detail
11.13.2 Daewoong Pharmaceutical Business Overview
11.13.3 Daewoong Pharmaceutical Anti-spasmodic Drugs Introduction
11.13.4 Daewoong Pharmaceutical Revenue in Anti-spasmodic Drugs Business (2019-2024)
11.13.5 Daewoong Pharmaceutical Recent Development
11.14 Acorda Therapeutics
11.14.1 Acorda Therapeutics Company Detail
11.14.2 Acorda Therapeutics Business Overview
11.14.3 Acorda Therapeutics Anti-spasmodic Drugs Introduction
11.14.4 Acorda Therapeutics Revenue in Anti-spasmodic Drugs Business (2019-2024)
11.14.5 Acorda Therapeutics Recent Development
11.15 SteriMax
11.15.1 SteriMax Company Detail
11.15.2 SteriMax Business Overview
11.15.3 SteriMax Anti-spasmodic Drugs Introduction
11.15.4 SteriMax Revenue in Anti-spasmodic Drugs Business (2019-2024)
11.15.5 SteriMax Recent Development
11.16 Emcure Pharmaceuticals
11.16.1 Emcure Pharmaceuticals Company Detail
11.16.2 Emcure Pharmaceuticals Business Overview
11.16.3 Emcure Pharmaceuticals Anti-spasmodic Drugs Introduction
11.16.4 Emcure Pharmaceuticals Revenue in Anti-spasmodic Drugs Business (2019-2024)
11.16.5 Emcure Pharmaceuticals Recent Development
11.17 Sawai Pharmaceutical
11.17.1 Sawai Pharmaceutical Company Detail
11.17.2 Sawai Pharmaceutical Business Overview
11.17.3 Sawai Pharmaceutical Anti-spasmodic Drugs Introduction
11.17.4 Sawai Pharmaceutical Revenue in Anti-spasmodic Drugs Business (2019-2024)
11.17.5 Sawai Pharmaceutical Recent Development
11.18 Orient Pharma
11.18.1 Orient Pharma Company Detail
11.18.2 Orient Pharma Business Overview
11.18.3 Orient Pharma Anti-spasmodic Drugs Introduction
11.18.4 Orient Pharma Revenue in Anti-spasmodic Drugs Business (2019-2024)
11.18.5 Orient Pharma Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
